Infinity Pharmaceuticals, Inc.

INFIQOTCHealthcare● Active

$0.00

+$0.00(+0.00%)

Market Cap$9076

P/E Ratio—

52W High$0.0001

52W Low$0.00001

Avg Volume60K

Open$0.00

Beta7.77

Earnings Financials Revenue

Infinity Pharmaceuticals, Inc. (INFIQ) Earnings: Dates, EPS & Revenue History

Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.

INFIQ · earnings · updated Jun 8, 2026

Latest Earnings

Q2 FY2023Report Date: Jun 30, 2023

EPS Actual

-$0.11

Revenue

$0.00B

Fiscal Period

Q2 FY2023

FY ends December

Report Date

Jun 30, 2023

After Market Close

INFIQ reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.

Next Earnings Date

Days Away

days

Expected Date

Sep 1, 2026

Fiscal Period

Q3 FY2026

Release Time

◌ Time TBD (Unconfirmed)

EPS Est.

—

Days Away85

Expected DateSep 1, 2026

Fiscal PeriodQ3 FY2026

Release TimeTime TBD (Unconfirmed)

EPS Est.—

EPS & Revenue vs. Estimates

Actual (Beat)

Actual (Miss)

Estimated

Earnings History

Period	Report Date	EPS Est.	EPS Actual	EPS Surpr.	Revenue	Rev. Est.	Rev. Surpr.
◌ Q3 FY2026	Aug 12, 2026	-$0.14	—	—	—	$0.00B	—
◌ Q2 FY2026	May 29, 2026	-$0.13	—	—	—	$0.00B	—
◌ Q2 FY2026	Apr 1, 2026	—	—	—	—	—	—
◌ Q3 FY2024	Aug 8, 2024	—	—	—	—	$0.00B	—
◌ Q2 FY2024	Jun 18, 2024	—	—	—	—	—	—
◌ Q1 FY2024	Feb 2, 2024	—	—	—	—	—	—
◌ Q4 FY2023	Dec 22, 2023	—	—	—	—	—	—
— Q2 FY2023	Jun 30, 2023	—	-$0.11	—	$0.00B	—	—

Q3 FY2026

Aug 12, 2026

EPS Actual

—

EPS Est.

-$0.14

EPS Surpr.

—

Revenue

—

Q2 FY2026

May 29, 2026

EPS Actual

—

EPS Est.

-$0.13

EPS Surpr.

—

Revenue

—

Q2 FY2026

Apr 1, 2026

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q3 FY2024

Aug 8, 2024

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q2 FY2024

Jun 18, 2024

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q1 FY2024

Feb 2, 2024

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q4 FY2023

Dec 22, 2023

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q2 FY2023

Jun 30, 2023

EPS Actual

-$0.11

EPS Est.

—

EPS Surpr.

—

Revenue

$0.00B

Analyst Estimates

Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.

EPS Estimates

Period	Low	Consensus	High	# Analysts
Q4 FY2029	$-0.15	$-0.15	$-0.15	1
Q3 FY2029	$-0.14	$-0.14	$-0.14	1
Q2 FY2029	$-0.13	$-0.13	$-0.13	1
Q1 FY2029	$-0.13	$-0.13	$-0.13	1
Q4 FY2028	$-0.12	$-0.12	$-0.12	1
Q3 FY2028	$-0.12	$-0.12	$-0.12	1

Revenue Estimates

Period	Low	Consensus	High	# Analysts
Q4 FY2029	$0.0B	$0.0B	$0.0B	1
Q3 FY2029	$0.0B	$0.0B	$0.0B	1
Q2 FY2029	$0.0B	$0.0B	$0.0B	1
Q1 FY2029	$0.0B	$0.0B	$0.0B	1
Q4 FY2028	$0.0B	$0.0B	$0.0B	1
Q3 FY2028	$0.0B	$0.0B	$0.0B	1

Earnings Price Reaction

Closing price one trading day before vs. one trading day after each earnings release.

Period	Report Date	EPS Beat/Miss	Price Before	Price After	1D Reaction
— Q2 FY2023	Jun 30, 2023	—	$0.21	$0.21	+0.24%
— Q1 FY2023	Mar 31, 2023	—	$0.18	$0.16	-11.11%
— Q4 FY2022	Dec 31, 2022	—	$0.56	$0.57	+2.70%
— Q3 FY2022	Sep 30, 2022	—	$1.19	$1.19	+0.00%

Q2 FY2023+0.24%

Report Date

Jun 30, 2023

EPS Beat/Miss

—

Price Before

$0.21

Price After

$0.21

Q1 FY2023-11.11%

Report Date

Mar 31, 2023

EPS Beat/Miss

—

Price Before

$0.18

Price After

$0.16

Q4 FY2022+2.70%

Report Date

Dec 31, 2022

EPS Beat/Miss

—

Price Before

$0.56

Price After

$0.57

Q3 FY2022+0.00%

Report Date

Sep 30, 2022

EPS Beat/Miss

—

Price Before

$1.19

Price After

$1.19

Beat Rate0 / 4 quarters

Largest Move-11.11% (Q1 FY2023)

Data: FMP /historical-price-eod/full · field: close

About Earnings & Data Methodology

Infinity Pharmaceuticals, Inc. (INFIQ) most recently reported earnings on June 30, 2023 for Q2 FY2023, posting EPS of $-0.11 (in line with the analyst consensus of —). The next INFIQ earnings date is expected around September 1, 2026.

Each quarter, investors track INFIQ earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. INFIQ revenue tab →

Earnings Glossary

EPS (Earnings Per Share)

Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.

Earnings Surprise %

(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.

Beat / Miss / In-Line

Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.

BMO / AMC

Before Market Open / After Market Close. Two windows when companies typically release results.

Fiscal Quarter

INFIQ's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.

Analyst Consensus

Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.

Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.

Revenue Price history Financial statements Forecast Dividends Market cap

Frequently asked questions

INFIQ earnings · 4 questions

Infinity Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. INFIQ typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; INFIQ historically reports after market close (AMC).

INFIQ earnings datewhen is INFIQ earningsINFIQ next earnings datewhen does INFIQ report earningsINFIQ earnings calendar

▸ Source: FMP · Infinity Pharmaceuticals, Inc. SEC filings · US GAAP · Infinity Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026